Patents Assigned to GW Pharma Limited
  • Publication number: 20180042842
    Abstract: The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.
    Type: Application
    Filed: May 4, 2017
    Publication date: February 15, 2018
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Geoffrey Guy
  • Publication number: 20170304217
    Abstract: The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids are one or more of: Cannabidiol (CBD); Cannabidivarin (CBDV); and Tetrahydrocannabivarin (THCV).
    Type: Application
    Filed: October 14, 2015
    Publication date: October 26, 2017
    Applicant: GW Pharma Limited
    Inventors: Vincenzo Di Marzo, Colin Stott, Keith Foster, Fabio Iannotti
  • Publication number: 20170290869
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
    Type: Application
    Filed: March 23, 2017
    Publication date: October 12, 2017
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
  • Publication number: 20170273913
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Application
    Filed: November 9, 2016
    Publication date: September 28, 2017
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Benjamin Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • Publication number: 20170246121
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: October 4, 2016
    Publication date: August 31, 2017
    Applicant: GW Pharma Limited
    Inventors: GEOFFREY GUY, Stephen Wright, Alice Mead, Charuta Joshi, Angus Wilfong
  • Patent number: 9675579
    Abstract: The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: June 13, 2017
    Assignee: GW Pharma Limited
    Inventors: Erin Rock, Linda Parker, Marnie Duncan, Colin Stott
  • Patent number: 9675654
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 13, 2017
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borrelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Patent number: 9669002
    Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 6, 2017
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Roger Pertwee
  • Publication number: 20170143642
    Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).
    Type: Application
    Filed: June 26, 2015
    Publication date: May 25, 2017
    Applicant: GW Pharma Limited
    Inventors: Colin Stott, Marnie Duncan, Thomas Hill
  • Publication number: 20170079933
    Abstract: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.
    Type: Application
    Filed: September 28, 2016
    Publication date: March 23, 2017
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Farideh Afshin Javid
  • Patent number: 9522123
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 20, 2016
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Benjamin Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • Publication number: 20160361290
    Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
    Type: Application
    Filed: March 14, 2016
    Publication date: December 15, 2016
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy
  • Publication number: 20160360721
    Abstract: The present invention relates to plants producing, as their major cannabinoid cannabichromenic acid (CBCA) or its neutral (decarboxylated) form cannabichromene (CBC), hereafter jointly referred to as CBC(A). It additionally relates to; a botanical material obtainable from said plants; a botanical raw material (BRM), an extract including a botanical drug substance (BDS) and a purified BDS; a formulation comprising the BRM, BDS, purified BDS or other extract; the use of the BRM, BDS, purified BDS or other extract in the manufacture of a medicament; a method of deriving plants yielding a high proportion of the in cannabinoid CBC(A) at the expense of other cannabinoids; a method of cultivating plants such that they yield a high proportion of the cannabinoid CBC(A) at the expense of other cannabinoids; and a method of extracting CBC(A) from said plants.
    Type: Application
    Filed: May 13, 2016
    Publication date: December 15, 2016
    Applicant: GW Pharma Limited
    Inventor: Etienne De Meijer
  • Patent number: 9474726
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: October 25, 2016
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Charuta Joshi, Angus Wilfong
  • Patent number: 9421187
    Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: August 23, 2016
    Assignee: GW Pharma Limited
    Inventors: Angelo Antonio Izzo, Francesca Borrelli, Stephen Wright
  • Publication number: 20160015682
    Abstract: The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.
    Type: Application
    Filed: November 20, 2012
    Publication date: January 21, 2016
    Applicant: GW Pharma Limited
    Inventors: Michael Cawthorne, Colin Stott, Stephen Wright
  • Patent number: 9205063
    Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: December 8, 2015
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Bettina Platt
  • Publication number: 20150328171
    Abstract: The present invention relates to the combination of the phytocannabinoid cannabidiol with therapeutic hypothermia for use in the treatment of neuroprotection or astroprotection.
    Type: Application
    Filed: June 10, 2013
    Publication date: November 19, 2015
    Applicant: GW Pharma Limited
    Inventors: Jose Martinez-Orgado, Geoffrey Guy
  • Patent number: 9168278
    Abstract: The invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: October 27, 2015
    Assignee: GW Pharma Limited
    Inventors: Geoffrey William Guy, Roger Pertwee
  • Patent number: 9125859
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: September 8, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura